“Dupilumab is a Predominant Treatment for Recalcitrant Bullous Pemphigoid” (2021) Archives of Clinical Case Reports, 4(1), pp. 1–4. Available at: https://somatopub.com/index.php/ACCR/article/view/17 (Accessed: 14 September 2026).